RxDoctor Payments Data

Graham Unis, MD

Hematology & Oncology · Salt Lake City, UTNPI 1417570045

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $757 of the $873 with a category attached, or 86.7%. 8 manufacturers reported payments, led by AVEO Pharmaceuticals, Inc. at 26.5% of the total. Reporting peaked in 2024 at $578 and has fallen 53.2% since, to $270 in 2025. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.

$873in general payments, 2019–2025

Across 10 payments — averaging $87.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AVEO Pharmaceuticals, Inc.$231
  • Jazz Pharmaceuticals Inc.$143
  • Incyte Corporation$125
  • Mallinckrodt Hospital Products Inc.$122
  • Novartis$102
  • Sanofi$100
  • plus $50 from 2 others

What the payments were for

  • Speaking & faculty fees$253%
  • Food & beverage$75787%
  • Education$9110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$873 in reported general payments places this provider in the 35th percentile of 77 hematology & oncology providers in Utah.

See all hematology & oncology providers in Utah

Medicare billing

Part B allowed, 2024
$14,606
Medicare patients
80
Services billed
127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →